

Disclaimer


- This information is provided in response to your unsolicited request and is intended for your scientific and/or educational purpose and is not intended for promotional use and its use is at your discretion.
- This information may contain substantive discussion of developmental compound(s) not approved for marketing and/or products approved for marketing but for uses, dosages, formulations, and/or populations different than those discussed in these materials.
- For marketed products, please consult the product labelling for information on the specific uses, dosages, formulations and populations for which they are approved. Refer to www.lilly.com for labelling material if it has not been provided.

The efficacy and safety of tirzepatide, a GIP and GLP-1 receptor agonist, after intensive lifestyle intervention in adults with overweight or obesity


STUDY DESIGN




INTERVENTIONS




INCLUSION CRITERIA



EFFICACY



SAFETY



Additional efficacy (not controlled for type I error): TZP MTD achieved greater improvement than with placebo for mean percent change in lipid parameters including decrease in triglycerides (-25.8% vs. 3%), decrease in non-HDL-C (-9.8% vs. 5.6%), decrease in total cholesterol (-3.0% vs. 5.2%), decrease in LDL-C (-6.1% vs. 6.1%), and increase in HDL-C (15.4% vs. 3.6%) along with decrease in mean change in SBP (-5.1 mmHg vs. 4.1 mmHg) from randomization at 72 weeks.

Conclusion: In this 72-week study in participants with overweight or obesity, after intensive lifestyle intervention, TZP MTD QW provided substantial and clinically meaningful reduction in body weight, and exhibited a safety profile comparable to other injectable incretin-based treatments used for weight management.